Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Recon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany ...

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

The FDA has released draft guidance seeking public feedback on regulatory approaches for generative AI-enabled medical devices, signalling a regulatory shift for AI in healthcare. Meanwhile, industry leaders warn that Germany must reform drug pricing to maintain pharmaceutical investment.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You must prepare for new FDA rules shaping AI medical device development and approval. Germany's drug pricing reform talk signals shifting investment risks in European pharma markets.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfdagenerative-aimedical-devicesdrug-pricinggermanypharma-investment